Nurix Therapeutics Inc. (NRIX)
NASDAQ: NRIXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NRIX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.40B
- P/E (TTM)
- 5.29
- EPS (TTM)
- $2.43
- Dividend yield
- None
- 52-week range
- 12.83 – 28.23
- Day range
- 12.83 – 13.67
- Volume / Avg
- 2.43M / 2.47M
- Beta
- —
- Shares outstanding
- 109.25M
52-week range
NRIX stock today
On Nov 20, NRIX ended the session at $12.85, shedding $0.755 (5.55%), versus the S&P 500's 3.70% decline. Shares are 54.5% below their 52-week high of $28.23, set on Aug 19, 2026 and 0.2% above the 52-week low of $12.83, near the bottom of the past year's range. NRIX is down 32.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 23.3%.
At 5.3x trailing earnings, Nurix Therapeutics trades below the peer-group median of 10.4x.
Summary generated from market data by MetaCap's automated system. Methodology
About Nurix Therapeutics
Company profileNurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Arthur T. Sands M.D., Ph.D.
- Headquarters
- Brisbane, CA
- Employees
- 317
- IPO year
- 2020
- Website
- nurixtx.com
Financial highlights
Full financialsIn fiscal 2025, Nurix Therapeutics generated $84.0 million in revenue, up 54.0% from fiscal 2024. Nurix Therapeutics reported a net loss of $264.5 million, compared with a loss of $193.6 million a year earlier. Operating margin was -340.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $83.98M | $54.55M | $76.99M | $38.63M | $29.75M |
| Growth | +53.95% | -29.15% | +99.31% | +29.84% | +66.95% |
| Net income | $-264.46M | $-193.57M | $-143.95M | $-180.36M | $-117.19M |
| EPS (diluted) | $-3.05 | $-2.88 | $-2.65 | $-3.71 | $-2.73 |
Analyst forecast
ForecastConsensus (14 analysts)
strong_buy
Avg. price target
$33.50+160.80%
- Strong buy 5
- Buy 8
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Aug/2026)
- Oct 12, 2026
- EPS actual vs est.
- $4.73 vs $-0.56
- Surprise
- +944.64%
NRIX news
All NRIX news- RHHBY Secures FDA Approval for Breast Cancer TreatmentNasdaqNVS, NRIX
- Nurix Appoints Arati Rao As Chief Medical Officer To Lead Clinical DevelopmentNasdaqNRIX, HEI.A
- Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical OfficerGlobeNewswire
- Nurix Shares Fall 40% After Sanofi Discontinues STAT6 Degrader ProgramNasdaqNRIX, SNY
- Why is Nurix Therapeutics stock collapsing 28% today?Investing.com
- Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272GlobeNewswire
- Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline AdvancesNasdaqNVO, LLY, NRIX
- Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?NasdaqKYMR, ARVN, NRIX
Nurix Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TYRATyra Biosciences Inc. | 20.12 | +1.98% | $1.39B | vs NRIX |
| ANABAnaptysBio Inc. | 46.63 | -1.62% | $1.39B | vs NRIX |
| ADRXADARx Pharmaceuticals Inc. | 12.79 | -9.68% | $1.42B | vs NRIX |
| SRPTSarepta Therapeutics Inc. | 13.33 | -5.93% | $1.43B | vs NRIX |
| KLRAKailera Therapeutics Inc. | 11.02 | -4.84% | $1.43B | vs NRIX |
| RAPPRapport Therapeutics Inc. | 23.16 | -1.82% | $1.37B | vs NRIX |
| DMRADamora Therapeutics Inc. | 23.22 | -4.44% | $1.44B | vs NRIX |
| QUREuniQure N.V. | 19.35 | -4.35% | $1.36B | vs NRIX |
Indexes, lists and sector
Nurix Therapeutics stock FAQ
What is Nurix Therapeutics's stock price today?
NRIX last traded at $12.85 as of Nov 20, 4:00 PM EST, down 5.55% on the day. Prices are delayed at least 15 minutes.
What is NRIX's P/E ratio?
NRIX trades at a trailing P/E ratio of 5.29, compared with a median of 10.4 for its closest peers.
Who is Nurix Therapeutics's CEO?
Dr. Arthur T. Sands M.D., Ph.D. is the chief executive officer of Nurix Therapeutics Inc., which has about 317 employees.
What is the NRIX 52-week high?
The 52-week high for NRIX is $28.23 and the 52-week low is $12.83. The stock is currently 54.5% below its high.